research collaboration and license AGREEMENTResearch Collaboration and License Agreement • March 1st, 2018 • Sangamo Therapeutics, Inc • Biological products, (no disgnostic substances) • New York
This Research Collaboration and License Agreement (the “Agreement”) is entered into as of December 28, 2017 (the “Effective Date”), by and between Pfizer Inc., a corporation organized and existing under the laws of Delaware and having a principal place of business at 235 East 42nd Street, New York, NY 10017 (“Pfizer”) and Sangamo Therapeutics, Inc., a corporation organized and existing under the laws of Delaware and having a principal place of business at 501 Canal Blvd., Richmond, CA 94804 (“Sangamo”). Pfizer and Sangamo may each be referred to herein individually as a “Party” and collectively as the “Parties.”
SANGAMO therapeutics, INC. RESTRICTED STOCK UNIT ISSUANCE AGREEMENTRestricted Stock Unit Issuance Agreement • March 1st, 2018 • Sangamo Therapeutics, Inc • Biological products, (no disgnostic substances) • California
LEASE AGREEMENT BETWEEN MARINA BOULEVARD PROPERTY, LLC, AS LANDLORD, AND SANGAMO THERAPEUTICS, INC., AS TENANTLease Agreement • March 1st, 2018 • Sangamo Therapeutics, Inc • Biological products, (no disgnostic substances) • Delaware
ContractSeparation Agreement • March 1st, 2018 • Sangamo Therapeutics, Inc • Biological products, (no disgnostic substances) • California
